IL-13 Recombinant Human - FAQs

查看更多产品信息 IL-13 Recombinant Human - FAQs (PHC0133)

2 个常见问题解答

What is R110Q?

R110Q is a polymorphic variant of wild type human IL-13 which occurs in 20% of the Caucasian population. This variant is associated with atopic diseases such as dermatitis and rhinitis. R110Q contains an amino acid substitution at position 110 replacing arginine residue with glutamine. R110Q shows slightly reduced binding affinity to IL-13Ra2 but binding affinity to the IL-13Ra1 is indistinguishable to the wild type IL-13. In fibroblast with low IRL-13Ra2 expression, the effect of R110Q on eotaxin induction is stronger than wild type IL-13 (Andrews A.L. et al 2007 & Ya-fang He et al. 2013; see links: https://www.sciencedirect.com/science/article/abs/pii/S0091674907008664 and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810544/pdf/aair-5-377.pdf).

Find additional tips, troubleshooting help, and resources within our Antibodies and Immunoassays Support Center.

Do you have a neutralizing monoclonal antibody for human IL-13?

Yes, the IL-13 Monoclonal Antibody (JES10-5A2) (Cat. No. AHC0132), clone ID JES10-5A2, has a neutralizing activity against human IL-13.

Find additional tips, troubleshooting help, and resources within our Antibodies and Immunoassays Support Center.